Recent evidence has shown that complement (C) opsonization of retroviruses can benefit the induction of specific CD8 
T cell responses by dendritic cells (DCs) (4). Here we demonstrate that beyond DCs, B cells can be involved in stimulating CD8
ϩ
T cells upon infection with complement-opsonized Friend virus (FV).
FV infection represents a well-established mouse retrovirus model suitable to study specific immune responses upon retroviral infection (18) . FV is a complex consisting of two viruses: a nonpathogenic replication-competent helper virus, Friend murine leukemia virus (F-MuLV), and the pathogenic replication-defective spleen focus-forming virus (SFFV). Infection of adult mice with the FV complex results in polyclonal proliferation of erythroid precursor cells, causing massive splenomegaly. Disease progresses to lethal erythroleukemia in susceptible mouse strains, which are unable to mount potent immune responses. Resistant mouse strains are able to control massive viral replication but never completely eradicate the virus. In these animals a chronic infection manifests, which is associated with the induction of regulatory T cells that suppress effector functions of virus-specific CD8 ϩ cytotoxic T lymphocytes (CTLs) (15, 30, 31) .
Studies using the surface subunit of F-MuLV envelope fused to green fluorescent protein (GFP) revealed that binding of FV envelope protein occurs through the cationic amino acid transporter mCAT-1, which is expressed on most cells (27) . FV targeted TER119 ϩ erythroblasts in vivo, but all hematopoietic cells, including B cells, were shown to interact with FV envelope protein (27) . In line with these studies, B cells have been reported as one of the target cell populations for FV infection in vivo (6, 8) and the primary reservoir for chronic virus (17) .
Inoculation of isolated Ig
ϩ splenic B cells with FV in vitro resulted in productive infection of these cells, which was more pronounced in the presence of a polyclonal B cell activator, lipopolysaccharide (LPS) (6, 8) . Since gammaretroviruses like FV require dividing cells for productive infection, polyclonal activation of B cells might be an advantage for viral spread.
Previous studies have shown that lactate dehydrogenaseelevating virus (LDV) infection caused a polyclonal activation of CD19 ϩ B cells, characterized by the expression of the early activation marker CD69 in vivo (1) . With the aim of studying mined by fluorescence-activated cell sorting (FACS) using FV glyco-Gag-specific monoclonal antibody clone 34 as described elsewhere (4) . At 14 days postinfection (dpi), we detected a significantly higher percentage of infected spleen B cells in FV/LDV-coinfected mice than in animals infected with FV alone (Fig. 1) . LDV-induced polyclonal activation of B cells might participate in enhanced infection of B cells. This hypothesis is further supported by the work of Tsuji-Kawahara et al. (29) , who recently showed that the B cells which are infected by FV are also the ones that are activated. These findings provide evidence that activation of B cells is necessary for FV infection. Nevertheless, we cannot exclude the finding that the lower percentage of FV-infected B cells also correlates with the higher frequency of FV-specific CTLs in FV-only-infected mice observed at 7 dpi by Robertson et al. (24) .
Since LDV does not directly induce polyclonal B cell activation (1), we used LPS, a polyclonal stimulator of B cell activation in our experiments in vitro. Using this experimental model, we could address the influence of B cell activation on FV infection levels. Infection of 10 6 spleen cells with 10,000 focus-forming units (FFU) of FV resulted in significant infection of B cells only in the presence of LPS (25 g/ml) as demonstrated by measuring the expression of FV glyco-Gag on B cells 2 dpi by FACS ( Fig. 2A) . Levels of FV infection of B cells correlated with activation as shown by the induction of CD69 expression (Fig. 2B) and proliferation (intracellular levels of Ki-67) (Fig. 2C and D) . These data further indicate the importance of B cell activation and proliferation for FV infection. Note that FV alone induced neither CD69 expression nor B cell proliferation (Fig. 2B to D) and showed little infection potential ( Fig. 2A) . Therefore, we used LPS-activated B cells in subsequent experiments to study the role of complement opsonization of FV in infection of B cells.
Several studies have demonstrated that retroviral infection of complement receptor-expressing cells can be enhanced by complement opsonization (2, 5, 12, 13, 16, 21, 26, 28) . Since mouse B cells express CR1 and CR2, prolonged interactions of B cells with C-opsonized virions are likely (16) . This might impact the infection of B cells in vivo. To evaluate this hypothesis, we infected B6 wild-type (wt) and B6 C3-knockout (KO) mice intravenously with 10,000 SFFU of FV. Experiments investigating the role of complement in FV infection of B cells and FV-specific CD8 ϩ T cell activation by B cells had to be performed in C57BL/6 mice, since C3-knockout mice are available only in the C57BL/6 background characterized by the resistant Fv2 r/r genotype. FV infection was determined 4 dpi by measuring the expression of FV glyco-Gag on B cells in the spleen. Compared to the infection in B6 wt mice, we found significantly lower levels of infected B cells in B6 C3 KO mice (Fig. 3A) . Of note, we did not observe any significant difference in the infection of complement-receptor-negative TER119 ϩ erythroid cells (data not shown). To further study the effects of opsonization on B cell infection, we opsonized F-MuLV in the presence of normal mouse serum (NMS), as a source of complement, at a dilution of 1:10 for 60 min at 37°C (F-MuLV-C). As a control, F-MuLV was incubated in heat-inactivated NMS (F-MuLV-hiC) or buffer alone (F-MuLV). Virus was ultracentrifuged (23,000 ϫ g, 2 h, 4°C), and the virus pellet was resuspended in medium. To confirm the opsonization pattern of the viruses, we applied F-MuLV-C and nonopsonized F-MuLV to a virus capture assay (VCA) as previously described (4). Using antibodies against mouse C3 in the VCA, we captured F-MuLV-C but not F-MuLV or F-MuLV-hiC, revealing the presence of C3 fragments only on effectively opsonized F-MuLV (data not shown). For the subsequent in vitro infection assays, we isolated splenic B cells using a mouse B cell isolation kit (Miltenyi Biotech) according to the manufacturer's instructions. Isolated B cell purity was more than 95%, as determined by flow cytometry. We infected 10 6 isolated LPS-stimulated (25-g/ml) splenic B cells with 1,000 FFU of nonopsonized (F-MuLV and F-MuLVhiC) and complement-opsonized (F-MuLV-C) virus in 100 l medium for 2 to 3 h at 37°C. Culture medium (400 l) was then added to each well, and the cells were cultured for another 20 h at 37°C. Input virus was then washed away, and B cells were further cultured in 1 ml RPMI-10% fetal calf serum (FCS) in the presence of LPS (25 g/ml). Application of culture supernatants from these infected B cells 5 dpi to FV-permissive Mus dunni cells revealed a productive infection of B cells with both F-MuLV and F-MuLV-C. However, significantly higher titers of virus were recovered from culture supernatants of B cells infected with F-MuLV-C (Fig. 3B) . Since F-MuLV opsonized in the presence of heat-inactivated serum did not show improved B cell infection, it is likely that complement proteins deposited on the viral surface rather than other serum proteins were responsible for the enhanced infection.
The effective control of FV infections in vivo involves both T cell and B cell responses, since FV-specific cytotoxic CD8 ϩ T lymphocytes (CTLs), CD4 ϩ T cells, and neutralizing antibodies (Abs) are required for recovery from infection (18) . The efficient induction of a CTL response is widely accepted to be a result of antigen presentation by DCs (3). Studies investigating the role of other professional antigen-presenting cells, especially B cells for the induction of CTL responses, are still underrepresented (10, 11, 14, 22, 23, 25) . Productive infection of B cells by FV suggests that viral proteins produced intracellularly are subject to presentation to CD8 ϩ T cells in an MHC (9) . Coculture of 1 ϫ 10 6 TCRtg CD8 ϩ T cells with 1 ϫ 10 6 LPS-stimulated B cells exposed to 1,000 FFU of F-MuLV or F-MuLV-hiC induced a slight expression of the early activation marker CD69 on CD8 ϩ T cells compared to nonloaded control B cells (Fig. 4A, left panel) . However, CD8 ϩ T cell activation was significantly enhanced when FVspecific CD8 ϩ T cells were cocultured with B cells loaded with C-opsonized F-MuLV (Fig. 4A, left panel) . In addition to CD69, another activation marker, CD25, was coexpressed on CD8 ϩ T cells when activated by F-MuLV-C-pulsed B cells 
CD8
ϩ T cell activation, since B cells loaded with either UVinactivated F-MuLV or F-MuLV-C were not able to provide any CD8 ϩ T cell stimulation (data not shown). Similar to our results in B cells, complement opsonization of F-MuLV or HIV was also shown to enhance the induction of virus-specific CTL responses by DCs both in vitro and in vivo (4) . Although infected B cells are able to efficiently activate FV-specific CD8 ϩ T cells, studies on lymphocytic choriomeningitis virus (LCMV) suggest that DCs initially induce primary CTL responses (19) . LCMV infects DCs, B cells, and macrophages, but the priming of LCMV-specific CTL responses depends mainly on DCs (20) . However, specific depletion of DCs does not completely abolish the CTL response against FV (7). Thus, all infected antigen-presenting cells, including B cells and macrophages, might help amplify the in vivo CTL response by stimulating primed CTLs to become activated.
Taken together, we showed that polyclonal activation of B cells promotes their infection with FV both in vitro and in vivo. Furthermore, complement opsonization of F-MuLV enhances infection of B cells. The enhanced infection correlates with a significant increase in the capacity of virus-loaded B cells to activate FV-specific CD8 ϩ T cells. The data shown here prove that complement opsonization serves as a natural adjuvant in the induction of antiviral CTL responses.
